Neurocrine/Takeda's Luvadaxistat Fails To Improve Schizophrenia Symptom Severity

Neurocrine Biosciences Inc (NASDAQ: NBIXannounces topline data from Phase 2 INTERACT study evaluating luvadaxistat (NBI-1065844/TAK-831) for the treatment of negative symptoms and cognitive impairment associated with schizophrenia.

  • Luvadaxistat is an oral, selective inhibitor with a high binding affinity to d-amino acid oxidase. It targets glutamate, an abundant neurotransmitter in the brain. 
  • The trial did not meet its primary endpoint as measured by the change from baseline on the PANSS NSFS (score used to assess schizophrenia symptom severity) at Day 84.
  • Luvadaxistat met secondary endpoints of cognitive assessment.
  • Takeda Pharmaceutical Co Ltd (NYSE: TAKgranted an exclusive license to Neurocrine Biosciences for seven pipeline programs, including luvadaxistat, in June last year.
  • The results from the study are being evaluated to determine the next steps for development activities.
  • Price Action: TAK shares are up 1.88% at $17.30, while NBIX shares are down by 5.03% at $103.93 in the pre-market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneralPhase 2 TrialSchizophrenia
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!